



PATENT


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	E. De Robertis	Examiner:	Not Yet Assigned
Serial No.	09/903,323	Group Art Unit:	1647
Filed:	July 11, 2001	Docket No.	510015-261
Title:	ENDODERM, CARDIAC, AND NEURAL INDUCING FACTORS— OLIGONUCLEOTIDES FOR EXPRESSING HUMAN FRAZZLED (FRZB-1) PROTEIN		

6/c

CERTIFICATE UNDER 37 CFR 1.8

I hereby certify that this correspondence and identified enclosures are being deposited with the United States Postal Service, first class mail, postage prepaid, under 37 C.F.R. 1.8 on the date indicated, and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on February 21, 2002.


Kelly Walsh

COMMUNICATION AND TRANSMITTAL OF CORRECTED SEQUENCE LISTING

Honorable Commissioner for Patents
Washington, D.C. 20231

Gentlemen:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed January 15, 2002, Applicants submit a corrected Sequence Listing. On reviewing the specification of the above-identified patent application, Applicants have noted that the sequences listed in the paper and machine-readable copy of the Sequence Listing previously submitted are not identical to the sequences recited in the specification and figures as originally filed with the Patent and Trademark Office. Specifically, errors exist in SEQ ID NO: 2, SEQ ID NO: 6, and SEQ ID NO: 10 of the sequences listed in the paper and machine-readable copy of the Sequence Listing; these sequences are not identical with those recited in the specification and figures of the originally-filed application. In order to correct this error, Applicants hereby submit a corrected Sequence Listing.

This corrected Sequence Listing is presented in a computer readable form and in a paper copy. The content of the paper and computer readable copies is the same. The corrected

Serial No. 09/903,323

510015-261


Sequence Listing includes no new matter, as the sequences themselves have not changed from their recitation in the specification and in the drawings. Specifically, the sequences in the Sequence Listing are identical to SEQ ID NO: 1-10 as shown in Figures 1-10 of the application as originally filed. There is therefore support for the sequences recited in this corrected Sequence Listing in the application as originally filed. This corrected sequence listing complies with the requirements of 37 C.F.R. §1.825(a) and §1.825(b), and is believed to place the application in compliance with 37 C.F.R. §§ 1.821-1.825.

A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures is enclosed with this transmittal.

If any further changes or corrections are required, the Examiner is respectfully requested to telephone the undersigned at (310) 788-5098.

Date: February 21, 2002

Respectfully submitted,



Charles Berman
Reg. No. 29,249

OPPENHEIMER WOLFF & DONNELLY LLP
2029 Century Park East
38th Floor
Los Angeles, CA 90067-3024
Phone: (310) 788-5098
FAX: (310) 788-5100